An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses
- 1 February 1999
- journal article
- clinical trial
- Published by Elsevier
- Vol. 103 (2) , 246-254
- https://doi.org/10.1016/s0091-6749(99)70498-7
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstructionJournal of Allergy and Clinical Immunology, 1998
- Montelukast, a Once-Daily Leukotriene Receptor Antagonist, in the Treatment of Chronic AsthmaA Multicenter, Randomized, Double-blind TrialArchives of internal medicine (1960), 1998
- Leukotriene activity modulation in asthma.Drugs, 1997
- Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter studyClinical Therapeutics, 1997
- Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroidsThorax, 1997
- Leukotrienes in AsthmaArchives of internal medicine (1960), 1996
- Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD 4) receptor antagonist, in patients with chronic asthmaJournal of Allergy and Clinical Immunology, 1996
- Leukotriene antagonists and synthesis inhibitors: New directions in asthma therapyJournal of Allergy and Clinical Immunology, 1996
- Anti-Leukotriene Agents: A New Direction in Asthma TherapyJournal of Asthma, 1996
- Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group.American Journal of Respiratory and Critical Care Medicine, 1994